Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pandoraon Jul 31, 2024 6:11pm
118 Views
Post# 36157161

RE:RE:This is curious

RE:RE:This is curious
Pareto8020 wrote: Yes someone at RBC is really a degenerate gambler and loading up or somebody out there knows something is coming in the near future.

Would be nice to get an update on the formulation progress, clinical trial they have to do before launching early 2025 and even what the heck Allergan is doing with the compound.  But we all know we'll get zero updates and news that does come usually creates more questions than answers.  Eventually the science will prevail and SBM will finally jettison upwards but why does Howard have to make this process so darn difficult and painful!!!  


743,500 total shares traded today. That is a bit of an anomaly in recent history. Hopefully the change is an indicator that the whole scene on Sirona will make a turn for the better. Not much room to be worse!


<< Previous
Bullboard Posts
Next >>